Christoph Nowak
Directeur Technique/Scientifique/R&D chez DIAMYD MEDICAL AB
Fortune : 581 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Anders Essen-Möller | M | 83 | 28 ans | |
Markus Jerling | M | 72 | 3 ans | |
Ulf Hannelius | M | 49 | 8 ans | |
Erik Kjellsson Nerpin | M | 63 | 12 ans | |
Daniel Ehrenstråhle | M | 50 | 1 ans | |
Mark Atkinson | M | 63 | 6 ans | |
Martina Widman | F | 43 | 8 ans | |
Niclas Holmgren | M | 32 | 1 ans | |
Karin Hehenberger | M | 52 | 3 ans | |
Carl Torbjörn Bäckström | M | 76 | 7 ans | |
Michael Owens | M | 68 | 1 ans | |
Anna Styrud | F | 63 | 14 ans | |
Theresa Comiskey Olsen | F | 61 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Maria-Teresa Essen-Möller | F | 54 | 15 ans | |
Anton Lindqvist | M | 44 | 11 ans | |
Karin Rosen | M | 57 | 1 ans | |
Eva Karlström | F | 60 | 4 ans | |
Stian Kildal | M | - | 1 ans | |
Kristofer Svensson | M | - |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | 2 ans |
Lars Christer Fedrik Fåhraeus | M | 59 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Paul de Potocki | M | 62 | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 21 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Christoph Nowak
- Réseau Personnel